Biotech Stocks on Investors' Radar -- Vertex Pharma, Nektar Therapeutics, CTI BioPharma, and Sage Therapeutics
NEW YORK, November 22, 2016 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com recalls the most recent performances of four Biotech companies, namely: Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Nektar Therapeutics (NASDAQ: NKTR), CTI BioPharma Corp. (NASDAQ: CTIC), and Sage Therapeutics Inc. (NASDAQ: SAGE). These equities belong to the Healthcare sector which ended slightly higher on Monday, November 21st, 2016, with the NYSE Health Care Index climbing just over 0.1%, and shares of health care companies in the S&P 500 rising nearly 0.2% as a group. Learn more about these stocks by downloading their comprehensive and free reports at:
Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock finished Monday's session 0.44% lower at $89.05 with a total trading volume of 1.28 million shares. The Company's shares have advanced 10.26% in the past month. The stock is trading 3.64% and 1.01% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Vertex Pharma, which engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases, have a Relative Strength Index (RSI) of 54.41.
On October 24th, 2016, research firm H.C. Wainwright downgraded the Company's stock rating from 'Buy' to 'Neutral', issuing a target price of $85 per share.
On November 07th, 2016, Vertex Pharma announced the results of a Phase 3 study of ORKAMBI® (lumacaftor/ivacaftor) in children with cystic fibrosis (CF) ages 6 through 11 who have two copies of the F508del mutation. The study met its primary endpoint of absolute change in lung clearance index (LCI2.5) through 24 weeks of treatment, demonstrating a statistically significant improvement in LCI2.5 among patients treated with ORKAMBI compared to placebo. LCI is a sensitive measure of lung function in early CF disease and the European Medicines Agency (EMA) agreed to the primary endpoint for this study. VRTX complete research report is just a click away and free at:
On Monday, shares in San Francisco, California headquartered Nektar Therapeutics recorded a trading volume of 1.24 million shares. The stock ended the session 3.16% lower at $13.50. The Company's shares have advanced 1.20% in the last one month. The stock is trading 9.86% below its 200-day moving average. Moreover, shares of Nektar Therapeutics, which develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the US, have an RSI of 42.16.
On November 08th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock.
On November 09th, 2016, Nektar Therapeutics announced that new Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and Natural Killer cell abundance directly in the tumor micro-environment and increase expression of PD-1 on these immune cells. The complimentary report on NKTR can be downloaded at:
Shares in Seattle, Washington headquartered CTI BioPharma Corp. closed the day 0.22% lower at $0.40 with a total trading volume of 417,233 shares. The stock has gained 13.05% in the previous three months. The Company's shares are trading 3.77% above their 50-day moving average. Additionally, shares of CTI BioPharma, which engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the US and internationally, have an RSI of 54.94.
On November 21st, 2016, CTI BioPharma announced that data from the randomized Phase 3 PERSIST-2 clinical trial comparing the investigational agent pacritinib, an oral multikinase inhibitor, with physician-specified best available therapy, including ruxolitinib, for treatment of patients with myelofibrosis whose baseline platelet counts are less than 100,000 per microliter will be presented in a late-breaking oral presentation at the upcoming 58th American Society of Hematology Annual Meeting, being held December 3rd-6th, 2016 in San Diego, California. Sign up for your complimentary research report on CTIC at:
At the close, shares in Cambridge, Massachusetts headquartered Sage Therapeutics Inc. ended the day at $51.03, which was a decline of 1.22%. The stock recorded a trading volume of 482,417 shares. The Company's shares have advanced 18.51% in the last one month and 33.73% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 13.40% and 35.98%, respectively. Furthermore, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 59.78.
On November 14h, 2016, research firm Stifel initiated a 'Buy' rating on the Company's stock, issuing a target price of $90 per share.
On November 16th, 2016, Sage Therapeutics announced that the European Medicines Agency has granted its PRIority MEdicines (PRIME) designation to SAGE-547 for the treatment of postpartum depression (PPD). The SAGE-547 application for the PRIME designation was based on the positive clinical results from the placebo-controlled 202A study of SAGE-547 in severe PPD. Get free access to your research report on SAGE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA